GlassScriptPhysician profile
Charles Lawrie
NPI 1720354806
$1,717,471.43
in general payments reported to CMS, 2019-2025
24 companies · $466K in 2025
The $466K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $114K · 2021: $213K · 2022: $97K · 2023: $400K · 2024: $398K · 2025: $466K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $574K · Consulting Fee: $404K · Royalty Or License: $145K · Travel and Lodging: $100K · Food and Beverage: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Honoraria: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $573,527.50 |
| Consulting Fee | $403,603.60 |
| Royalty Or License | $145,117.40 |
| Travel and Lodging | $100,047.09 |
| Food and Beverage | $23,671.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,000.00 |
| Honoraria | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,589,170.64 | 2019-2025 | Rosa, Persona, Arcos |
| Medtronic, INC. | $43,416.56 | 2021-2025 | Aquamantys(Tm), Plasmablade(Tm) |
| Microport Orthopedics INC | $23,664.96 | 2019-2022 | |
| Medtronic USA, INC. | $21,276.02 | 2019-2020 | |
| Smith+Nephew, INC. | $15,482.18 | 2021-2025 | Pico 14, Pico, Renasys Touch |
| Ignite Orthomotion LLC | $9,248.19 | 2023-2024 | |
| Stryker Corporation | $3,242.40 | 2019-2025 | Mako, Triathlon, Insignia |
| Kci USA, INC. | $3,014.28 | 2019-2021 | |
| Think Surgical, INC. | $2,170.69 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $1,911.68 | 2022-2023 | Seglentis |
| Medacta USA, INC. | $1,277.53 | 2019-2024 | |
| Davol INC. | $900.00 | 2024 | |
| Uoc USA INC | $798.00 | 2024-2025 | Momentum, Conformity, U-Motion II and Ustar II, Conformity and U-Motion II |
| Depuy Synthes Sales INC. | $764.50 | 2019-2025 | Monovisc, Orthovisc |
| Solventum Corporation | $600.00 | 2025 | V.A.C. Veraflo Cleanse Choice, Abthera, Prevena |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthalign INC | $150.00 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $136.11 | 2022-2024 | Iovera, Exparel, Zilretta |
| Biocomposites INC | $92.21 | 2021 | |
| Boston Scientific Corporation | $68.37 | 2025 | Intracept |
| Ossio INC | $27.74 | 2021 | |
| Integra Lifesciences Corporation | $25.11 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Molnlycke Health Care US, LLC | $19.89 | 2024 | Avance, Mepilex Border Post-Op Ag |
| Heraeus Medical, LLC. | $14.37 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$33,432.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lawrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.